|
Malignant neoplasm of pancreas
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<b>Rationale</b>: Successful treatment of pancreatic cancer remains a challenge due to desmoplasia and prevalence of KRAS mutation.
|
30128034 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer exhibits a high frequency of K-ras gene mutations; however, it is not known whether DOC-2 expression is altered in these tumors.
|
11406647 |
2001 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
|
16166322 |
2005 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer is usually initiated by mutation of KRAS and aberrant expression of SHH.
|
16367914 |
2006 |
|
Malignant neoplasm of pancreas
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is characterized by oncogenic activation of K-Ras and inactivation of the cell cycle inhibitor p16(INK4a) .
|
22049925 |
2012 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS.
|
29367463 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences.
|
8157353 |
1994 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
K-ras gene mutations were detected in 26 of the 28 (93%) pancreatic cancers.
|
14767735 |
2004 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS2 mutations were also detected in pancreatic duct juice from patients with pancreatic cancer.
|
15782177 |
2004 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
K-ras gene point mutation and its style at codon 12 of human pancreatic cancer cell line Patu8988 were detected by using polymerase chain reaction with special sequence primers (PCR-SSP) and sequence analysis.
|
18777594 |
2008 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS2 mutations were identified in 31 of 39 (80%) of the familial versus 28 of 36 (78%) of the sporadic pancreatic cancers.
|
19064568 |
2008 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
|
19208745 |
2009 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS is mutated in more than 90% of pancreatic cancer patients, and oncogenic KRAS contributes to pancreatic cancer tumorigenesis and progression.
|
19273243 |
2009 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation was detected in none of the AIP cases and 10/11 PC cases (91%, Pearson χ(2) = 22.16, p < 0.001) or 10/16 PC cases (63%) accounting for PC cases with failed DNA amplification.
|
21997479 |
2011 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
|
23599154 |
2013 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS: feeding pancreatic cancer proliferation.
|
24388967 |
2014 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
K-ras gene mutations are common in patients with pancreatic cancer (PC); however, their prognostic value for PC remains inconclusive.
|
27183870 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
|
27225938 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation is often present in many hard-to-treat tumors such as colon and pancreatic cancer and it is tightly linked to serious alterations in the normal cell metabolism and clinical resistance to chemotherapy.In 1931, the winner of the Nobel Prize in Medicine, Otto Warburg, stated that cancer was primarily caused by altered metabolism interfering with energy processing in the normal cell.
|
27323830 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS-related proteins in pancreatic cancer.
|
27595930 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful.
|
27978579 |
2017 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer.
|
29059158 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
K-Ras mutations are widespread in PC cases (90%), with mutations detectable as early as pancreatic intraepithelial neoplasias and in later metastatic stages alike; therefore, these mutations in K-Ras are obvious drivers and potential targets for PC therapy.
|
29199014 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
|
29229669 |
2018 |